A proposal to rename polycystic ovary syndrome (PCOS) is generating discussion in the medical literature, with a correspondence published in The Lancet weighing in on the suggested shift in terminology.
What Is Being Proposed
Helena J Teede and colleagues have put forward a new name for the condition: polyendocrine metabolic ovarian syndrome, abbreviated as PMOS. According to The Lancet correspondence, the proposal emerged from a global consensus process rather than a unilateral clinical decision, lending it a degree of international collaborative weight.
Why the Current Name Is Considered Problematic
A central concern driving the renaming effort is that the existing term is regarded as misleading. The word "polycystic" implies the presence of pathological cysts on the ovaries — a characterisation that does not accurately reflect the underlying biology for many of those affected. Researchers and clinicians have long noted that the name can cause confusion both among patients and within broader medical contexts.
The proposed replacement, PMOS, is intended to foreground the condition's metabolic and multisystem dimensions more explicitly. The disorder involves hormonal dysregulation and metabolic disruption that extends well beyond the ovaries, and advocates of the new label argue the current name fails to capture that complexity.
Reception in the Literature
The authors of the Lancet correspondence expressed support for the broader intention behind the change, acknowledging the value of better representing the metabolic and multisystem burden associated with the condition. At the same time, the act of publishing a formal response signals that the proposal is not without nuance or ongoing deliberation within the research community.
Nomenclature changes in medicine carry practical consequences. Diagnostic criteria, patient records, research databases, and clinical guidelines are all organised around established terminology, meaning a shift in name — even a well-motivated one — requires careful coordination across institutions and specialties.
Broader Context
The condition currently known as PCOS is one of the more common endocrine disorders, and its name has been a subject of periodic scrutiny for years. Efforts to revise it reflect a wider trend in medicine toward terminology that more accurately describes pathophysiology rather than surface-level anatomical observations that may not apply universally.
Whether PMOS will gain traction as the preferred term remains to be seen. The global consensus process cited as the foundation for the proposal may lend it credibility, but adoption across clinical and research settings typically unfolds gradually and unevenly.
The full correspondence is available via The Lancet.